Evidence map›Paper›PMID 40201183›Full record

ArticleFrontiers in immunology2025

Linda Reiling, Kristina E M Persson, Fiona J McCallum, Nimmo Gicheru, Samson M Kinyanjui, Chetan E Chitnis, Freya J I Fowkes, Kevin Marsh, James G Beeson

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Linda ReilingDepartment of Life Sciences, Burnet Institute of Medical Research and Public Health, Melbourne, VIC, Australia.
Kristina E M PerssonDepartment of Laboratory Medicine, Lund University, Lund, Sweden.
Fiona J McCallumAustralian Defence Force Malaria and Infectious Disease Institute, Enoggera, QLD, Australia.
Nimmo GicheruCentre for Geographic Medicine Research (Coast), Kenya Medical Research Institute - Wellcome Trust Research Programme, Kilifi, Kenya.
Samson M KinyanjuiCentre for Geographic Medicine Research (Coast), Kenya Medical Research Institute - Wellcome Trust Research Programme, Kilifi, Kenya.
Chetan E ChitnisDepartment of Parasites and Insect Vectors, Pasteur Institute, Paris, France.
Freya J I FowkesDepartment of Life Sciences, Burnet Institute of Medical Research and Public Health, Melbourne, VIC, Australia.
Kevin MarshCentre for Geographic Medicine Research (Coast), Kenya Medical Research Institute - Wellcome Trust Research Programme, Kilifi, Kenya.
James G BeesonDepartment of Life Sciences, Burnet Institute of Medical Research and Public Health, Melbourne, VIC, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Antibodies targeting the blood-stage of Methods: Serum samples from malaria-exposed children and adults in Kenya were examined for their ability to inhibit Results and Discussion: The loss of PfRH1 and PfRH2b substantially impacted on susceptibility to inhibitory antibodies, suggesting that variation in the use of these ligands contributes to immune evasion. The effect was less prominent with loss of PfRH2a. Differential inhibition of the knockout and parental lines points to PfRH1 and PfRH2b as targets of acquired growth inhibitory antibodies whereas PfRH2a appeared to be a minor target. There was limited relatedness of the inhibitory responses between different isolates or compared to parasites with deletions of erythrocyte-binding antigens. This further suggests that there is a substantial amount of antigenic diversity in invasion pathways to facilitate immune evasion. These findings provide evidence that PfRH1 and PfRH2b are significant targets of inhibitory antibodies and variation in their expression may facilitate immune evasion. Targeting of multiple invasion ligands in vaccine design is likely to be required to achieve potent inhibitory antibodies and protective efficacy against malaria.

Indexed as

Antibodies, ProtozoanAntigens, ProtozoanImmune EvasionMalaria, FalciparumPlasmodium falciparumProtozoan ProteinsReticulocytesAdultChildChild, PreschoolErythrocytesHumansKenyaMerozoitesAntibodies, ProtozoanAntigens, ProtozoanProtozoan ProteinsRh2b protein, Plasmodium falciparumimmune evasioninhibitory antibodiesP. falciparumphenotypic variationreticulocyte binding homologuesRH proteins

Identifiers

PMID40201183
PMCPMC11975925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.